Provider buys Febridx for $25 per test. From the $41 reimbursement rate, the provider make back the cost of the test plus the difference to incentivise use of the test. Provider makes $16 profit per use of the test.
This really should have been included in the announcement, no mention from LDX on what the impact of the PLA code is for sales. Clarity and confirmation is important in market updates.
LDX Price at posting:
3.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)